Photodynamic therapy for low risk prostate cancer

Ritch, Chad R.; Punnen, Sanoj

doi:10.1136/bmj.j575

Cited by 6 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A summary of all significant examples of ICG-NPs developed for these applications has been inserted in Table 1. PDT is an emerging, minimally invasive cancer treatment based on the production of ROS in response to a source of light, the presence of oxygen and a photosensitizer (i.e., ICG) (ZhuGe et al, 2019). Although this option seems promising for many cancers (Gross et al, 2003;Ritch and Punnen, 2017), selective delivery of the photosensitizers at target tissues/cells remains insufficient for successful clinical use (Zhen et al, 2013). Since PDT could generate an antitumor immune response, ICG-loaded liposomes were studied in combination with NIR irradiation, demonstrating suppression of brain tumor growth and suggesting the potential application for the treatment of tumors near the brain surface (Shibata et al, 2019).…”

Section: Icg-nps and Cancer: Preclinical Studiesmentioning

confidence: 99%

Indocyanine Green Nanoparticles: Are They Compelling for Cancer Treatment?

et al. 2020

View full text Add to dashboard Cite

Indocyanine green (ICG) is a Food and Drug Administration-approved near-infrared fluorescent dye, employed as an imaging agent for different clinical applications due to its attractive physicochemical properties, high sensitivity, and safety. However, free ICG suffers from some drawbacks, such as relatively short circulation half-life, concentration-dependent aggregation, and rapid clearance from the body, which would confine its feasible application in oncology. Here, we aim to discuss encapsulation of ICG within a nanoparticle formulation as a strategy to overcome some of its current limitations and to enlarge its possible applications in cancer diagnosis and treatment. Our purpose is to provide a short but exhaustive overview of clinical outcomes that these nanocomposites would provide, discussing opportunities, limitations, and possible impacts with regard to the main clinical needs in oncology.

show abstract

Section: Icg-nps and Cancer: Preclinical Studiesmentioning

confidence: 99%

Indocyanine Green Nanoparticles: Are They Compelling for Cancer Treatment?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Given that all of these patients fell into a low risk category preoperatively, some authors have questioned if PDT treatment was worth these adverse events. 52 While PDT is well studied, the outcomes are comparable to other focal therapies. Newer photosensitizers targeting Prostate-Specific Membrane Antigen (PSMA) are also being developed, allowing for more targeted and specific release of reactive species in areas expressing PSMA which may theoretically improve disease targeting and treatment outcomes.…”

Section: Contemporary Treatments In Prostate Cancer Focal Therapymentioning

confidence: 99%

Contemporary treatments in prostate cancer focal therapy

Ahdoot

Lebastchi

Türkbey

et al. 2019

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose: Radical treatments for prostate cancer are associated with significant morbidity, including incontinence and erectile dysfunction. Advances in the field of prostate MRI and desire to reduce treatment morbidities have led to a rapid growth in focal treatments for prostate cancer. Here, we review novel focal prostate cancer treatments and their associated recent clinical data, with a particular focus on data reported within the last 24 months. Recent findings: High Intensity Focal Ultrasound (HIFU), Focal Laser Ablation (FLA), Irreversible Electroporation (IRE), Focal Cryotherapy, and Photodynamic Therapy (PDT) have been used as treatment modalities for localized prostate cancer treatment. Despite the great variety of treatment techniques, each of these modalities is characterized by a significant rate of prostate cancer persistence within treatment zones (6–50%) and the presence of residual cancer within the prostate on re-biopsy (24–49%). These treatments, however, are associated with very low rates of high-grade complications, rare incontinence, and only mild or transient reductions in erectile function. The most common adverse events are urinary tract infections, hematuria, and urinary retention. Summary: Prostate cancer focal therapy is an attractive option for well selected patients due to its low complication profile, however long-term oncologic outcome is still lacking and early recurrence rates are high, limiting the ability of most urologic associations from endorsing its routine use.

show abstract

“…In turn, the initial stage of the disease is difficult to address and could be prone to over-treatment with invasive surgery and/or radio- and chemotherapy. At this stage, active surveillance is often proposed despite the risk to develop more advanced disease could not be certainly defined and, in order to overcome this limitation, vascular-targeted PDT (VPDT), is becoming a more and more considered therapeutic option (Gheewala et al, 2017; Ritch and Punnen, 2017).…”

Section: Vascular Pdt For Low-risk Prostate Cancermentioning

confidence: 99%

Light-Induced Therapies for Prostate Cancer Treatment

et al. 2019

View full text Add to dashboard Cite

Prostate cancer (PC) is one of the most widespread tumors affecting the urinary system and the fifth-leading cause from cancer death in men worldwide. Despite PC mortality rates have been decreasing during the last years, most likely due to an intensification of early diagnosis, still more than 300,000 men die each year because of this disease. In this view, researchers in all countries are engaged in finding new ways to tackle PC, including the design and synthesis of novel molecular and macromolecular entities able to challenge different PC biological targets, while limiting the extent of unwanted side effects that significantly limit men's life quality. Among this field of research, photo-induced therapies, such as photodynamic and photothermal therapies (PDT and PTT), might represent an important advancement in PC treatment due to their extremely localized and controlled cytotoxic effect, as well as their low incidence of side effects and tumor resistance occurrence. Based on these considerations, this review aims to gather and discuss the last 5-years literature reports dealing with the synthesis and biological activity of molecular conjugates and nano-platforms for photo-induced therapies as co-adjuvant or combined therapeutic modalities for the treatment of localized PC.

show abstract

Photodynamic therapy for low risk prostate cancer

Abstract: No substitute for active surveillance yet

Cited by 6 publications

References 10 publications

Indocyanine Green Nanoparticles: Are They Compelling for Cancer Treatment?

Indocyanine Green Nanoparticles: Are They Compelling for Cancer Treatment?

Contemporary treatments in prostate cancer focal therapy

Light-Induced Therapies for Prostate Cancer Treatment

Contact Info

Product

Resources

About